Ruxolitinib’s benefit in patients with myelofibrosis can be assessed using a number of methods that are easily accessed in the community setting, according to a post hoc analysis of data from COMFORT-I trial involving 150 individuals.
Investigators evaluated changes over 12 weeks in spleen size, patient-reported outcomes, body weight, and serum albumin levels in 5 ruxolitinib-treated subgroups divided based on spleen length. Among the results:
- Ruxolitinib was linked with improved spleen volume in all subgroups, including those with worsening spleen length.
- Body weight and serum albumin levels also improved.
- Greater reductions in spleen length were linked with prolonged overall survival.
Miller C, Komrokji R, Mesa R, Sun W, Montgomery M, Verstovsek S. Practical measures of clinical benefit with ruxolitinib therapy: An exploratory analysis of COMFORT-I. [Published online ahead of print May 12, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.05.015.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al